Who Generates Higher Gross Profit? United Therapeutics Corporation or Jazz Pharmaceuticals plc

Biopharma Giants' Gross Profit Battle: Jazz vs. United Therapeutics

__timestampJazz Pharmaceuticals plcUnited Therapeutics Corporation
Wednesday, January 1, 201410554570001162636000
Thursday, January 1, 201512222770001396725000
Friday, January 1, 201613825870001526100000
Sunday, January 1, 201715085050001619600000
Monday, January 1, 201817693780001429100000
Tuesday, January 1, 201920338310001331200000
Wednesday, January 1, 202022146500001375200000
Friday, January 1, 202126534780001563000000
Saturday, January 1, 202231188570001789600000
Sunday, January 1, 202333986270002070000000
Loading chart...

Cracking the code

A Tale of Two Biopharma Giants: Gross Profit Showdown

In the competitive world of biopharmaceuticals, United Therapeutics Corporation and Jazz Pharmaceuticals plc have been vying for dominance in gross profit generation since 2014. Over the past decade, Jazz Pharmaceuticals has consistently outperformed its rival, boasting a remarkable 65% increase in gross profit from 2014 to 2023. In contrast, United Therapeutics saw a more modest growth of 78% during the same period.

By 2023, Jazz Pharmaceuticals reached a gross profit of approximately $3.4 billion, a significant leap from its $1.1 billion in 2014. Meanwhile, United Therapeutics achieved a gross profit of around $2.1 billion, up from $1.2 billion in 2014. This data highlights Jazz Pharmaceuticals' strategic prowess in maximizing profitability, while United Therapeutics continues to hold its ground with steady growth. As the biopharma landscape evolves, these two companies remain key players to watch.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025